Bahaa E. Elgendy, PhD

Assistant Professor
Anesthesiology
Center for Clinical Pharmacology

Biochemistry, Biophysics, and Structural Biology Program
Computational and Systems Biology Program

  • Academic Research Building, Room 605, St. Louis College of Pharmacy

  • belgendy@wustl.edu

  • http://www.elgendylab.com/

  • Medicinal chemistry with a broad goal of drug design and organic synthesis

Research Abstract:

The main focus of Dr. Elgendy’s research group is drug design and organic synthesis. He designs and synthesize novel small organic molecules as modulators of nuclear hormone receptors for the therapeutic treatment of cancer, fatty liver diseases, Alzheimer’s Disease, and Atherosclerosis. Also, he synthesizes complex and diverse molecules to combat multi-drug resistant bacteria and anti-viral agents against HCV and ZIKV and other microbes. Dr. Elgendy incorporates computational methods such as quantitative structure activity relationships, pharmacophore modeling, and virtual screening in his drug discovery pipeline to accelerate the process of drug discovery and optimization.

Selected Publications:

Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, McCommis KS, Elgendy B. Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening. Biomedicines 2022;10(2):365.

Elgendy B, Griffett K, Hegazy L, Di Fruscia P, Sample K, Schoepke E, Kamenecka TM, Burris TP. Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorg Chem. 2022119:105540. PMID: 34902646

Fang Y, Hegazy L, Finck BN, Elgendy B. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. J Med Chem 202164(24):17545–17571. PMID: 34889100

Elagawany M, Maram L, Elgendy B. Novel synthesis of benzotriazolyl alkyl esters: an unprecedented CH2 insertion. RSC Adv 2021;11(13):7564–7569.

Goher SS, Elgendy B. Structure-Based Design of Estrogen-Related Receptors Modulators. Nucl Recept Springer, Cham; 2021. p. 79–109.

Elagawany M, Hegazy L, Elgendy B. Catalyst- and organic solvent-free synthesis of thioacids in water. Tetrahedron Letters. 2019 June; 60(30):2018.

Shahien M, Elagawany M, Sitaula S, Goher SS, Burris SL, Sanders R, Avdagic A, Billon C, Hegazy L, Burris TP, Elgendy B. Modulation of estrogen-related receptors subtype selectivity: Conversion of an ERRβ/γ selective agonist to ERRα/β/γ pan agonists. Bioorg Chem 2020;102:104079.

Goher SS, Griffett K, Hegazy L, Elagawany M, Arief MMH, Avdagic A, Banerjee S, Burris TP, Elgendy B. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Bioorg Med Chem Lett. 2019 Feb 1;29(3):449-453.

Elgendy BM, Goher SS, Hegazy LS, Arief MMH, Burris TP. Recent Advances in the Medicinal Chemistry of Liver X Receptors. J Med Chem. 2018 Dec 27;61(24):10935-10956.

Elagawany M, Hegazy L, Cao F, Donlin MJ, Rath N, Tavis J, Elgendy B. Identification of 4-isopropyl–thiotropolone as a novel anti-microbial: regioselective synthesis, NMR characterization, and biological evaluation. RSC advances. 2018 August; 8:29967.

Flaveny CA, Griffett K, El-Gendy BEDM, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 2015;28(1):42–56. PMID: 26120082

Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nat Commun. 2014;5. PMID: 25536025

Last Updated: 2/20/2022 8:59:39 PM

Back To Top

Follow us: